Log in

NASDAQ:GMDAGamida Cell Stock Price, Forecast & News

$4.41
-0.13 (-2.86 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.38
Now: $4.41
$4.69
50-Day Range
$4.35
MA: $5.06
$6.34
52-Week Range
$2.60
Now: $4.41
$7.70
Volume223,278 shs
Average Volume221,389 shs
Market Capitalization$106.81 million
P/E RatioN/A
Dividend YieldN/A
Beta2.07
Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II studies in patients with severe aplastic anemia. It is also developing NAM-NK, an innate immunotherapy, which is in Phase I studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GMDA
CUSIPN/A
CIKN/A
Phone972-2659-5666

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.44 per share

Profitability

Net Income$-34,350,000.00

Miscellaneous

Employees79
Market Cap$106.81 million
Next Earnings Date8/4/2020 (Estimated)
OptionableNot Optionable

Receive GMDA News and Ratings via Email

Sign-up to receive the latest news and ratings for GMDA and its competitors with MarketBeat's FREE daily newsletter.

Gamida Cell (NASDAQ:GMDA) Frequently Asked Questions

How has Gamida Cell's stock been impacted by COVID-19 (Coronavirus)?

Gamida Cell's stock was trading at $4.23 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GMDA shares have increased by 4.3% and is now trading at $4.41. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Gamida Cell?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gamida Cell in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Gamida Cell.

When is Gamida Cell's next earnings date?

Gamida Cell is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Gamida Cell.

How were Gamida Cell's earnings last quarter?

Gamida Cell Ltd (NASDAQ:GMDA) released its earnings results on Thursday, May, 21st. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.43) by $0.12. View Gamida Cell's earnings history.

What price target have analysts set for GMDA?

7 Wall Street analysts have issued 12-month price targets for Gamida Cell's shares. Their forecasts range from $13.00 to $20.00. On average, they expect Gamida Cell's share price to reach $16.33 in the next year. This suggests a possible upside of 270.4% from the stock's current price. View analysts' price targets for Gamida Cell.

Has Gamida Cell been receiving favorable news coverage?

Media headlines about GMDA stock have trended somewhat positive this week, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Gamida Cell earned a news sentiment score of 0.8 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news about Gamida Cell.

Who are some of Gamida Cell's key competitors?

What other stocks do shareholders of Gamida Cell own?

Who are Gamida Cell's key executives?

Gamida Cell's management team includes the following people:
  • Dr. Julian Adams Ph.D., CEO & Director (Age 65, Pay $740k)
  • Mr. Shai Lankry CPA, M.B.A., Chief Financial Officer (Age 44, Pay $353k)
  • Dr. Ronit Simantov, Chief Medical Officer (Age 55, Pay $587k)
  • Mr. Joshua D. Hamermesh MBA, Chief Bus. Officer (Age 48, Pay $508k)
  • Mr. Thomas J. Klima, Chief Commercial Officer (Age 48, Pay $392k)

When did Gamida Cell IPO?

(GMDA) raised $50 million in an IPO on Friday, October 26th 2018. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Needham & Company Oppenheimer & Co. was co-manager.

What is Gamida Cell's stock symbol?

Gamida Cell trades on the NASDAQ under the ticker symbol "GMDA."

How do I buy shares of Gamida Cell?

Shares of GMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Gamida Cell's stock price today?

One share of GMDA stock can currently be purchased for approximately $4.41.

How big of a company is Gamida Cell?

Gamida Cell has a market capitalization of $106.81 million. The company earns $-34,350,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis. Gamida Cell employs 79 workers across the globe.

What is Gamida Cell's official website?

The official website for Gamida Cell is www.gamida-cell.com.

How can I contact Gamida Cell?

Gamida Cell's mailing address is 5 NAHUM HAFZADI STREET GIVAAT SHAUL, JERUSALEM L3, 91340. The company can be reached via phone at 972-2659-5666 or via email at [email protected]

This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.